Prithviraj Bose Selected Research

Drug Tapering

1/2020	Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
1/2019	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
1/2019	New Concepts of Treatment for Patients with Myelofibrosis.
1/2018	Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Prithviraj Bose Research Topics

Disease

42	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 03/2016
38	Neoplasms (Cancer) 01/2024 - 11/2009
25	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023 - 07/2014
16	Anemia 04/2024 - 12/2016
14	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2023 - 11/2016
11	Cytopenia 06/2023 - 06/2017
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 01/2016
10	Splenomegaly 11/2023 - 12/2016
9	Systemic Mastocytosis 06/2023 - 01/2018
9	Leukemia 01/2021 - 11/2009
8	Polycythemia Vera 01/2024 - 12/2016
8	Thrombocytopenia (Thrombopenia) 01/2023 - 05/2017
7	Essential Thrombocythemia 01/2024 - 12/2016
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2022 - 11/2009
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 07/2014
6	Multiple Myeloma 01/2018 - 01/2013
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 01/2018
4	Thrombocytosis (Thrombocythemia) 11/2023 - 01/2017
4	Philadelphia Chromosome 01/2020 - 01/2017
3	Invasive Fungal Infections 03/2024 - 04/2011
3	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 06/2012
3	Thrombosis (Thrombus) 11/2023 - 12/2016
3	Infections 11/2023 - 01/2020
3	Pleural Effusion (Pleural Effusions) 11/2022 - 01/2018
3	Fibrosis (Cirrhosis) 01/2022 - 07/2018
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 11/2014
2	Leukocytosis (Pleocytosis) 11/2023 - 01/2019
2	Disease Progression 06/2023 - 03/2016
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 01/2019
2	Eosinophilia 01/2021 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020 - 01/2018
2	Inflammation (Inflammations) 08/2019 - 01/2019
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018 - 11/2014
2	Lymphoma (Lymphomas) 06/2017 - 11/2014
2	Hemorrhage 02/2017 - 12/2016
2	Breast Neoplasms (Breast Cancer) 01/2016 - 11/2009
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2014 - 11/2014
1	Herpes Zoster 03/2024
1	Histoplasmosis 03/2024
1	Opportunistic Infections (Opportunistic Infection) 03/2024
1	Nausea 11/2023

Drug/Important Bio-Agent (IBA)

34	ruxolitinibIBA 03/2024 - 03/2016
14	venetoclaxIBA 05/2023 - 01/2017
13	Janus KinasesIBA 03/2024 - 03/2016
13	Janus Kinase InhibitorsIBA 03/2024 - 12/2016
7	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 10/2023 - 06/2017
7	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 06/2023 - 06/2017
7	ibrutinibIBA 12/2021 - 11/2016
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2013
6	Activin Receptors (Activin Receptor)IBA 10/2023 - 12/2016
6	LigandsIBA 11/2021 - 12/2016
6	Bortezomib (Velcade)FDA Link 01/2021 - 06/2009
5	fedratinibIBA 03/2024 - 01/2019
5	InterferonsIBA 01/2024 - 12/2016
5	Sorafenib (BAY 43-9006)FDA Link 11/2023 - 01/2016
5	Hemoglobins (Hemoglobin)IBA 06/2023 - 01/2017
5	avapritinibIBA 06/2023 - 01/2019
5	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 01/2018
5	alvocidib (flavopiridol)IBA 01/2018 - 06/2012
4	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023 - 09/2015
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 11/2016
4	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2022 - 12/2016
4	Decitabine FDA Link 01/2021 - 01/2020
3	Hydroxyurea (Hydrea)FDA LinkGeneric 11/2023 - 01/2017
3	Dasatinib (BMS 354825)FDA Link 11/2022 - 01/2018
3	Rituximab (Mabthera)FDA Link 12/2021 - 11/2014
3	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
3	midostaurinIBA 11/2019 - 01/2018
3	Vorinostat FDA Link 01/2019 - 01/2016
3	Janus Kinase 1IBA 01/2019 - 12/2016
3	Histone Deacetylase InhibitorsIBA 01/2018 - 12/2016
3	Apoptosis Regulatory ProteinsIBA 01/2017 - 09/2014
2	ACE-011IBA 04/2024 - 01/2017
2	CytokinesIBA 01/2024 - 01/2023
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 01/2018
2	HepcidinsIBA 10/2023 - 01/2022
2	RNA Splicing FactorsIBA 06/2023 - 01/2022
2	Histones (Histone)IBA 01/2023 - 09/2014
2	Reticulin (Reticular Fiber)IBA 01/2022 - 10/2018
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2016
2	imetelstatIBA 01/2022 - 01/2017
2	isavuconazoleIBA 01/2021 - 10/2018
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 01/2020
2	givinostatIBA 06/2020 - 01/2017
2	CateninsIBA 01/2020 - 01/2019
2	bcr-abl Fusion ProteinsIBA 01/2020 - 11/2009
2	Brentuximab VedotinIBA 01/2019 - 12/2014
2	Janus Kinase 2IBA 01/2019 - 06/2017
2	Lysine (L-Lysine)FDA Link 12/2018 - 09/2014
2	Proteasome InhibitorsIBA 01/2018 - 11/2014
2	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2018 - 09/2015
2	PRM-151IBA 01/2018 - 01/2017
2	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2018 - 09/2015
2	Antifibrotic AgentsIBA 12/2016 - 12/2016
2	Imatinib Mesylate (Gleevec)FDA Link 06/2012 - 11/2009
1	Interferon-alpha (Interferon Alfa)IBA 11/2023
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2023

Therapy/Procedure

49	Therapeutics 03/2024 - 11/2009
16	Drug Therapy (Chemotherapy) 11/2023 - 01/2015
4	Drug Tapering 01/2020 - 01/2018